# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Henry Holliday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI007-SYN-TD
- Date: 1873-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Martin Beaumont, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for diagnosis of cavitary pulmonary tuberculosis: sputum, chest X-ray, baseline tests, public-health report, home isolation, and alcohol assessment with a safety assessment. **S**

## Objective

Hemoglobin: 12.6 g/dL (low); White cell count: 9.4 10*3/uL; Platelets: 412 10*3/uL (high); ALT: 34 U/L; AST: 38 U/L; Total bilirubin: 0.6 mg/dL; Alkaline phosphatase: 92 U/L; GGT: 78 U/L (high); Albumin: 3.4 g/dL (low); Creatinine: 0.86 mg/dL; eGFR: 124 mL/min/1.73 m²; Glucose: 90 mg/dL; HbA1c: 5.2%; Visual acuity, right eye (ETDRS letters): 85; Visual acuity, left eye (ETDRS letters): 85; AUDIT: 15; AUDIT-C: 9; PHQ-9: 6. All results are synthetic.

BP 112/70 mmHg; pulse 104 bpm; respirations 20/min; temperature 37.8 °C; oxygen saturation 95% on room air; weight 58 kg; BMI 18.3 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance; Alcohol use disorder, mild, with binge drinking. Strengths and supports remain part of the care plan. **S**

## Medication changes

- No medication changes. **S**

## Plan

- Infectious diseases consultation to confirm the regimen and plan monitoring for cavitary pulmonary tuberculosis in a man who drinks heavily. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025) **S**
- Standard treatment: isoniazid, rifampin, pyrazinamide, and ethambutol for eight weeks, then isoniazid and rifampin for eighteen weeks, by video-observed therapy with the health department, with pyridoxine. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016) **S**
- Monitoring: monthly symptom and weight check, sputum smear and culture monthly until two consecutive cultures are negative, liver tests at two weeks and monthly because of alcohol, and vision checks while on ethambutol. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006) **S**
- Public health: same-day report to the local health department, home isolation until noninfectious, and a contact investigation of his household, coworkers, and patients led by the health department. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005) **S**
- Alcohol care: brief intervention at diagnosis, a goal of no alcohol during treatment, counseling with a substance-use counselor, medication offered, AUDIT-C at each visit, and a safety review with the 988 Suicide & Crisis Lifeline at every visit. Guideline: Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024) **S**
